Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping

The progression of Parkinson's disease (PD) seems to vary according to the disease stage, which greatly influences the management of PD patients. However, the underlying mechanism of progression in PD remains unclear. This study was designed to explore the progressive pattern of iron accumulation at different stages in PD patients. Sixty right‐handed PD patients and 40 normal controls were recruited. According to the disease stage, 45 patients with Hoehn–Yahr stage ≤ 2.5 and 15 patients with Hoehn–Yahr stage ≥ 3 were grouped into early‐stage PD (EPD) and late‐stage PD (LPD) groups, respectively. The iron content in the cardinal subcortical nuclei covering the cerebrum, cerebellum and midbrain was measured using quantitative susceptibility mapping (QSM). The substantia nigra pars compacta (SNc) showed significantly increased QSM values in the EPD patients compared with the controls. In the LPD patients, while the SNc continued to show increased QSM values compared with the controls and EPD patients, the regions showing increased QSM values spread to include the substantia nigra pars reticulata (SNr), red nucleus (RN) and globus pallidus (GP). Our data also indicated that iron deposition was more significant in the GP internal segment (GPi) than in the GP external segment. No other regions showed significant changes in QSM values among the groups. Therefore, we were able to confirm a regionally progressive pattern of iron accumulation in the different stages of PD, indicating that iron deposition in the SNc is affected exclusively in the early stages of the disease, while the SNr, RN and GP, and particularly the GPi segment, become involved in advanced stages of the disease. This is a preliminary study providing objective evidence of the iron‐related progression in PD. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  P. Yu,et al.  Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson’s disease , 2015, Neuroscience.

[2]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[3]  Xuemei Huang,et al.  Higher iron in the red nucleus marks Parkinson's dyskinesia , 2013, Neurobiology of Aging.

[4]  Chunlei Liu,et al.  Whole brain susceptibility mapping using compressed sensing , 2012, Magnetic resonance in medicine.

[5]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[6]  P D Griffiths,et al.  Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. , 1993, Dementia.

[7]  Ferdinand Schweser,et al.  Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.

[8]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[9]  F. Ye,et al.  Basal ganglia iron content in Parkinson's disease measured with magnetic resonance , 1996, Movement disorders : official journal of the Movement Disorder Society.

[10]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[11]  M. I. Argyropoulou,et al.  MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease , 2005, Journal of Neurology.

[12]  D. Dexter,et al.  Neurodegenerative diseases and therapeutic strategies using iron chelators. , 2015, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[13]  Ke Xu,et al.  Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients. , 2013, Magnetic resonance imaging.

[14]  D. Mash,et al.  Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice , 1991, Experimental Neurology.

[15]  Martin Styner,et al.  Imaging nigral pathology and clinical progression in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[16]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[17]  T. Liimatainen,et al.  T1ρ and T2ρ MRI in the evaluation of Parkinson’s disease , 2010, Journal of Neurology.

[18]  I. Elovaara,et al.  Clinical MRI for iron detection in Parkinson's disease. , 2013, Clinical imaging.

[19]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[20]  Chunlei Liu,et al.  Association between increased magnetic susceptibility of deep gray matter nuclei and decreased motor function in healthy adults , 2015, NeuroImage.

[21]  J. Connor,et al.  Iron in the brain. , 2009, Nutrition reviews.

[22]  Nan Luo,et al.  Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[24]  Xuemei Huang,et al.  Quantitative susceptibility mapping of the midbrain in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[25]  Wei Cao,et al.  A method for estimating and removing streaking artifacts in quantitative susceptibility mapping , 2015, NeuroImage.

[26]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[27]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[28]  W. Geldenhuys,et al.  Brain Iron Toxicity: Differential Responses of Astrocytes, Neurons, and Endothelial Cells , 2007, Neurochemical Research.

[29]  Christian Langkammer,et al.  Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan , 2014, Human brain mapping.

[30]  Bing Wu,et al.  Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition , 2011, NeuroImage.

[31]  Chiou-Lian Lai,et al.  PARKINSON’S DISEASE PATIENTS , 2008 .

[32]  J. Obeso,et al.  Pathophysiology of the basal ganglia in Parkinson's disease , 2000, Trends in Neurosciences.

[33]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[34]  Xue Xiao,et al.  Integrated Laplacian‐based phase unwrapping and background phase removal for quantitative susceptibility mapping , 2014, NMR in biomedicine.

[35]  Wei Li,et al.  Susceptibility‐weighted imaging and quantitative susceptibility mapping in the brain , 2015, Journal of magnetic resonance imaging : JMRI.

[36]  Kemin Chen,et al.  Region‐specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping , 2015, Human brain mapping.

[37]  Stephen R Lord,et al.  Clinical and physiological assessments for elucidating falls risk in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[38]  Tian Liu,et al.  Internal structures of the globus pallidus in patients with Parkinson’s disease: evaluation with quantitative susceptibility mapping (QSM) , 2015, European Radiology.

[39]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping , 2011, NeuroImage.